UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of January, 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
GlaxoSmithKline plc
 
GSK publishes provisional dividend dates
 
 
 
 
 
GSK announces the following dividend dates for 2020.
 
 
Results
announcement
date
Ex-dividend
date
Record date
 
Last date for
DRIP elections
 
Payment date
 
Q1 2020
 
Wednesday
29 April
 
Thursday
14 May
 
Friday
15 May
 
Wednesday
17 June
 
Thursday
9 July
 
Q2 2020
 
Wednesday
29 July
 
Thursday
13 August
 
Friday
14 August
 
Thursday
17 September
 
Thursday
8 October
 
Q3 2020
 
Wednesday
28 October
 
Thursday
12 November
 
Friday
13 November
 
Monday
21 December
 
Thursday
14 January 2021
 
Q4 2020
(Final)
 
Wednesday
3 February 2021
 
Thursday
18 February 2021
 
Friday
19 February 2021 
 
Tuesday  
16 March 2021
 
Thursday
8 April 2021
 
 
These dates are indicative and may be subject to change.  
 
 
 
 
Victoria Whyte
Company Secretary
 
8 January 2020
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: January 08, 2020 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc